Pfizer Ltd Stock Analysis

BSE: 500680 | NSE: PFIZER | Pharmaceuticals & Drugs | Large Cap

BSE Share Price 02-Dec-2022 18:01
4592.00 36.55 (0.80%)

DeciZen - Make an Informed Decision on Pfizer

Overall Rating

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

Pfizer Price Chart

P/E Ratio (SA) :
34.25
Market Cap :
21,007.4 Cr.
52-wk low :
4,056
52-wk high :
5,230.1
Bole Toh?

1. Is Pfizer Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Pfizer Ltd is a good quality company.

2. Is Pfizer Ltd undervalued or overvalued?

The key valuation ratios of Pfizer Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Pfizer Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Pfizer Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Pfizer:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Pfizer Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 14.3%18.8%11.3%14.2%10.6%13.9%14.4%15.5%17.4%23.5%-
Value Creation Index 0.00.3-0.20.1-0.20.00.10.20.61.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,0491,1121,8532,0121,9661,9692,0822,1522,2392,6112,456
YoY Gr. Rt. %-6%66.7%8.6%-2.3%0.1%5.7%3.4%4%16.6%-
Adj EPS 71.273.732.363.952.977.789.4106.8108133.4134.1
YoY Gr. Rt. %-3.5%-56.2%98%-17.3%46.9%15.1%19.5%1.1%23.5%-
BVPS (₹) 567.8220.6431.3472.9528.7586.5658.2742.2523.1626.1637.5
Adj Net Profit 213220148292242355409489494610613
Cash Flow from Ops. -1613211334532933297.8323427667-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.7%5.8%7.9%16.6%
Adj EPS 7.2%20.3%14.3%23.5%
BVPS 1.13.4-1.719.7
Share Price 14.7% 19.1% 1.2% -6.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 14.218.711.214.110.613.914.415.317.123.221.2
Op. Profit Mgn % 17.621.620.621.617.825.527.326.931.832.131.9
Net Profit Mgn % 20.319.8814.512.318.119.722.722.123.425
Debt to Equity 00000000000
Working Cap Days 185169143160154165185199200181331
Cash Conv. Cycle 332120-1-10-40-27-4622223

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 21.20%

Net Profit is growing at healthy rate in last 3 years 14.26%

Sales growth has been subdued in last 3 years 7.85%

Sales growth is not so good in last 4 quarters at -1.00%

Latest Financials - Pfizer Ltd.

Standalone Consolidated
TTM EPS (₹) 134.1 30
TTM Sales (₹ Cr.) 2,456 772
BVPS (₹.) 637.5 0
Reserves (₹ Cr.) 2,870 965
P/BV 7.20 0.00
PE 34.25 153.24
From the Market
52 Week Low / High (₹) 4056.00 / 5230.10
All Time Low / High (₹) 27.50 / 6164.80
Market Cap (₹ Cr.) 21,007
Equity (₹ Cr.) 45.8
Face Value (₹) 10
Industry PE 37.8

Management X-Ray of Pfizer :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Pfizer

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Pfizer Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Pfizer on 02-Dec-2022 18:01 is : 4,592.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Dec-2022 18:01 the market cap of Pfizer stood at ₹ 21,007.4.
The latest PE ratio of Pfizer as of 02-Dec-2022 18:01 is 34.25.
The latest PB ratio of Pfizer as of 02-Dec-2022 18:01 is 7.20
The 52-week high of Pfizer is ₹ 5,230.1 and the 52-week low is ₹ 4,056.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Pfizer is ₹ 2,456 ( Cr.) .

About Pfizer Ltd

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.

Business area of the company

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Awards

2001

  • OPPI Brand Excellence Award for Minipress XL.

2002

  • Express Pharma Biz Award for overall performance.
  • Rated as one of India's most socially responsive companies. Awarded by FICCI-Socio Economic Development Foundation for our Social Responsiveness.

2003

  • Voted as the 5 'Most Respected Company' in the Pharma sector (Business World).
  • Corporate Advertising Campaign won a Silver Award at the ABBY-All India Awards for Creative Excellence. Gelusil brand received a Silver Award for printing advertising.
  • Golden Peacock National Training Special Commendation for Training practices.

2004

  • Ranked 5 among all pharmaceutical companies, with respect to corporate image, field-force, and promotional programs (AC Nielsen-ORG Marg 'Corporate Image Survey').
  • Ranked 1 among all Pharma MNCs & 4 among all Pharma Companies by Business World.
  • Kewal Handa, CFO Pfizer Limited receives the ‘India CFO 2004 - Excellence in Finance in an MNC’ by International Market - Assessment Group.

2005

  • Golden Peacock Innovative Service Award for Prime MD Today (Daxid).
  • PC Quest 'Best IT Implementation Users Choice' award for OPTILEARN.
  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and #3 among all pharmaceuticals, in the Business World survey.

2006

  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and 3 among all pharmaceuticals, in the Business World survey.
  • Kewal Handa, Managing Director Pfizer, awarded the Bharat Shiromani award for his outstanding contribution in the pharmaceutical industry.

2007

  • Reader’s Digest Trusted Brand Asia - Gold Award 2007’ in the vitamin and health supplement category for Becosules.

2008

  • Frost & Sullivan Brand Strategy Leadership Award for Becosules in the Indian Dietary Supplement Market.
  • Pfizer India was recently conferred the ‘Innovative Training Practices’ Award for promoting effective and optimum utilization of human resource through education and training by the Indian Society for Training and Development (ISTD).

2009

  • Pfizer Limited (India) conferred the Multinational Pharmaceutical Company of the Year by Frost & Sullivan.

2010

  • Pfizer Limited awarded the Most Admired Pharmaceutical Company of the Year by Pharma Leaders Magazine.
  • Kewal Handa, Country Manager - Pfizer Limited recognized as Pharma Professional of the Year by Pharma Leaders Magazine.
  • Pfizer wins the Community Engagement Award at the Asia Responsible Entrepreneurship Awards 2010 in India.

2011

  • Pfizer India has been recognized as one of The Best Companies to Work For by Business Today magazine.

2012

  • J.D. Power and Associates has honored the MS LifeLines call center with certification for an outstanding customer service experience. This is the first time J.D. Power has recognized a pharmaceutical call center. Click Here.

2013

  • GBCHealth Business Leadership Award - in recognition for the Global Health Fellows program. This award is given annually to a company or business leader with a deep and long-term commitment to global health that extends beyond the business objective of the company itself. Caroline Roan will be accepting the award on behalf of Pfizer.
  • Business Action on Health Award in Application of Core Competence for Global Health Fellows Program (commendation). Oonagh Puglisi will be accepting the award for the GHF program.
  • Business Action on Health Award in Partnership/Collective Action for Advancing Cancer & Tobacco Control in China Program. Danlong Feng, Corporate Affairs Director, Pfe China, will be accepting the award.
  • QUESTAR Award - The International Awards Festival for Excellence in Video Communications Pfizer was awarded the Grand -- best of category -- in Annual Reports in the 2013 Questar Awards.
  • Telly Award - For over a quarter century, the Telly statuette has been a symbol of creative excellence. Pfizer was awarded - Bronze at the 2013 Telly's for online videos.

Milestones:

  • 1849: Charles Pfizer & Company established. 1' product for treatment of intestinal worms is a success.
  • 1880: Pfizer manufactures Citric Acid. Rapid growth on the back of aerated drinks demand.
  • 1882: Alexander Fleming discovers penicillin.
  • 1944: Pfizer finds a way to mass-produce Penicillin.
  • 1950: Terramycin, the 1st pharmaceutical sold in the US under the Pfizer label.
  • 1950: India operation launched, with HQ in Mumbai.
  • 1966: Pfizer listed on the Bombay Stock Exchange.
  • 1989: Dolonex (Feldene) launched in India.
  • 1993: Amlogard (Norvasc) launched in India.
  • 1996: Launch of MinipressXL, an anti hypertensive drug.
  • 1998: Launch of Viagra, for erectile dysfunction.
  • 1999: Pfizer listed on the National Stock Exchange.
  • 2000: Launch of Magna& a unique hospital antibiotic.
  • 2002: Futuristic tablet manufacturing Goa plant commissioned in a record 13 months.
  • 2003 Completes merger with Parke-Davis (India) Ltd.
  • 2005: Announces merger with Pharmacia Healthcare ltd.
  • 2006: Launch of LYRICA (pregaballn for treatment of neuropathic pain)
  • 2008: Launch of Champix - a non-nicotine smoking cessation prescription drug.
  • 2010: Launch of Prevenar 13, vaccine for prevention of pneumococcal disease and included later in India’s Universal Immunization Programe.
  • 2015: Completed merger with Wyeth Limited.
  • 2016: Launched Xeljanz-the first oral Janus Kinase (JAK) inhibitor.
  • 2017: Acquires 2 breakthrough brands- Meronem, Neksium.
  • 2019: Reorganizes into 3 distinct business units: Pfizer Biopharma Group, UpJohn and Consumer Healthcare. New purpose and values unveiled.
  • 2019: Launches novel anti-bacterial Zavicefta in India.
  • 2020: Launch of Zinforo, a noval cephalosporin indicated for treatment of adult patients with community- acquired Pneumonia.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now